Work

A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report On the Poor Risk Patients

Year: 2012

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v120.21.3584.3584

Authors: Sucha Nand, Megan Othus, John E. Godwin, Cheryl L Willman, Thomas Norwood, Harry Paul Erba, Dianna Howard, Steven E. Coutre, Frederick R. Appelbaum

Institutions: Loyola University Medical Center, Loyola Medicine, Fred Hutch Cancer Center, University of New Mexico, UNM Comprehensive Cancer Center, University of Washington, University of Michigan, University of Kentucky, Stanford Medicine, Stanford University

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2557413167

FWCI: 0.385

Cites:

Cited by: 5

Related to: 10